Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer

Niranjan Awasthi, Margaret Schwarz, Roderich E. Schwarz

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). Sunitinib (Su) is a novel, multi-target receptor tyrosine kinase inhibitor that has antitumour activities. This study tested the benefits of combined gemcitabine and sunitinib in PDAC. Methods: Cell viability and protein expression were evaluated by WST-1 assay and Western blotting. Tumour growth and survival experiments were performed in murine xenografts. Results: In PDAC cells, Gem, Su and Su + Gem, respectively, caused 28%, 22% and 48% inhibition in proliferation at 100 nM. In endothelial cells, Gem, Su and Su + Gem, respectively, caused 49%, 32% and 72% inhibition in proliferation. In fibroblasts, Gem, Su and Su + Gem, respectively, caused 65%, 14% and 79% inhibition in proliferation. Su increased apoptosis, as evidenced by the cleavage of caspase-3 and PARP-1 proteins. Net tumour growth compared with controls in the Gem, Su and Su + Gem groups was 57%, 6% and 1%, respectively. Intratumoral proliferative activity was reduced by 33%, 82% and 75% in the Gem, Su and Su + Gem groups, respectively, compared with controls. Median survival in the control, Su, Gem and Su + Gem groups was 16, 21, 24 and 30 days, respectively (P= 0.007). Conclusions: These findings support a combination approach using multi-target antiangiogenic agents such as sunitinib with standard gemcitabine therapy in the treatment of PDAC.

Original languageEnglish (US)
Pages (from-to)597-604
Number of pages8
JournalHPB
Volume13
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

gemcitabine
Pancreatic Neoplasms
Adenocarcinoma
sunitinib

Keywords

  • combination therapy
  • gemcitabine
  • pancreatic cancer
  • sunitinib

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. / Awasthi, Niranjan; Schwarz, Margaret; Schwarz, Roderich E.

In: HPB, Vol. 13, No. 9, 09.2011, p. 597-604.

Research output: Contribution to journalArticle

Awasthi, Niranjan ; Schwarz, Margaret ; Schwarz, Roderich E. / Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. In: HPB. 2011 ; Vol. 13, No. 9. pp. 597-604.
@article{e9575190f1f64eec829810b24dc2b980,
title = "Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer",
abstract = "Background: Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). Sunitinib (Su) is a novel, multi-target receptor tyrosine kinase inhibitor that has antitumour activities. This study tested the benefits of combined gemcitabine and sunitinib in PDAC. Methods: Cell viability and protein expression were evaluated by WST-1 assay and Western blotting. Tumour growth and survival experiments were performed in murine xenografts. Results: In PDAC cells, Gem, Su and Su + Gem, respectively, caused 28{\%}, 22{\%} and 48{\%} inhibition in proliferation at 100 nM. In endothelial cells, Gem, Su and Su + Gem, respectively, caused 49{\%}, 32{\%} and 72{\%} inhibition in proliferation. In fibroblasts, Gem, Su and Su + Gem, respectively, caused 65{\%}, 14{\%} and 79{\%} inhibition in proliferation. Su increased apoptosis, as evidenced by the cleavage of caspase-3 and PARP-1 proteins. Net tumour growth compared with controls in the Gem, Su and Su + Gem groups was 57{\%}, 6{\%} and 1{\%}, respectively. Intratumoral proliferative activity was reduced by 33{\%}, 82{\%} and 75{\%} in the Gem, Su and Su + Gem groups, respectively, compared with controls. Median survival in the control, Su, Gem and Su + Gem groups was 16, 21, 24 and 30 days, respectively (P= 0.007). Conclusions: These findings support a combination approach using multi-target antiangiogenic agents such as sunitinib with standard gemcitabine therapy in the treatment of PDAC.",
keywords = "combination therapy, gemcitabine, pancreatic cancer, sunitinib",
author = "Niranjan Awasthi and Margaret Schwarz and Schwarz, {Roderich E.}",
year = "2011",
month = "9",
doi = "10.1111/j.1477-2574.2011.00333.x",
language = "English (US)",
volume = "13",
pages = "597--604",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer

AU - Awasthi, Niranjan

AU - Schwarz, Margaret

AU - Schwarz, Roderich E.

PY - 2011/9

Y1 - 2011/9

N2 - Background: Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). Sunitinib (Su) is a novel, multi-target receptor tyrosine kinase inhibitor that has antitumour activities. This study tested the benefits of combined gemcitabine and sunitinib in PDAC. Methods: Cell viability and protein expression were evaluated by WST-1 assay and Western blotting. Tumour growth and survival experiments were performed in murine xenografts. Results: In PDAC cells, Gem, Su and Su + Gem, respectively, caused 28%, 22% and 48% inhibition in proliferation at 100 nM. In endothelial cells, Gem, Su and Su + Gem, respectively, caused 49%, 32% and 72% inhibition in proliferation. In fibroblasts, Gem, Su and Su + Gem, respectively, caused 65%, 14% and 79% inhibition in proliferation. Su increased apoptosis, as evidenced by the cleavage of caspase-3 and PARP-1 proteins. Net tumour growth compared with controls in the Gem, Su and Su + Gem groups was 57%, 6% and 1%, respectively. Intratumoral proliferative activity was reduced by 33%, 82% and 75% in the Gem, Su and Su + Gem groups, respectively, compared with controls. Median survival in the control, Su, Gem and Su + Gem groups was 16, 21, 24 and 30 days, respectively (P= 0.007). Conclusions: These findings support a combination approach using multi-target antiangiogenic agents such as sunitinib with standard gemcitabine therapy in the treatment of PDAC.

AB - Background: Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). Sunitinib (Su) is a novel, multi-target receptor tyrosine kinase inhibitor that has antitumour activities. This study tested the benefits of combined gemcitabine and sunitinib in PDAC. Methods: Cell viability and protein expression were evaluated by WST-1 assay and Western blotting. Tumour growth and survival experiments were performed in murine xenografts. Results: In PDAC cells, Gem, Su and Su + Gem, respectively, caused 28%, 22% and 48% inhibition in proliferation at 100 nM. In endothelial cells, Gem, Su and Su + Gem, respectively, caused 49%, 32% and 72% inhibition in proliferation. In fibroblasts, Gem, Su and Su + Gem, respectively, caused 65%, 14% and 79% inhibition in proliferation. Su increased apoptosis, as evidenced by the cleavage of caspase-3 and PARP-1 proteins. Net tumour growth compared with controls in the Gem, Su and Su + Gem groups was 57%, 6% and 1%, respectively. Intratumoral proliferative activity was reduced by 33%, 82% and 75% in the Gem, Su and Su + Gem groups, respectively, compared with controls. Median survival in the control, Su, Gem and Su + Gem groups was 16, 21, 24 and 30 days, respectively (P= 0.007). Conclusions: These findings support a combination approach using multi-target antiangiogenic agents such as sunitinib with standard gemcitabine therapy in the treatment of PDAC.

KW - combination therapy

KW - gemcitabine

KW - pancreatic cancer

KW - sunitinib

UR - http://www.scopus.com/inward/record.url?scp=80051913597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051913597&partnerID=8YFLogxK

U2 - 10.1111/j.1477-2574.2011.00333.x

DO - 10.1111/j.1477-2574.2011.00333.x

M3 - Article

C2 - 21843259

AN - SCOPUS:80051913597

VL - 13

SP - 597

EP - 604

JO - HPB

JF - HPB

SN - 1365-182X

IS - 9

ER -